Clinical trials: Basal Cell Carcinoma of Skin
Basal Cell Carcinoma
Pilot LDE225 in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors
This is a prospective single-center, open label, pilot study to investigate the safety and efficacy of LDE225 in patients with locally advanced or metastatic basal cell carcinoma.
- Trial name
- NCT01529450
- Testing
- LDE225
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Anne Chang
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
This pilot clinical trial studies isolated limb perfusion with melphalan in treating patients with stage IIIB-IV melanoma or sarcoma.
- Conditions
- Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma
- Trial name
- NCT02507076
- Testing
- isolated limb perfusion, melphalan, quality-of-life assessment
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
High Intensity Focused Ultrasound vs. Cryotherapy in the Treatment of Basal Cell Carcinomas and Bowen's Disease in Adults
This prospective, randomized, controlled, and single-blinded non-inferiority clinical trial compare the efficacy and tolerability of high intensity focused ultrasound (HIFU) to standard cryotherapy in the treatment of low-risk…
- Conditions
- Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Bowen's Disease, BCC
- Trial name
- HIFUvsCRYO (NCT07384078)
- Testing
- High Intensity Focused Ultrasound, Cryotherapy
- Where
- Finland
- Volunteers
- 294 people
- Sponsor
- Jussi Salonen
Advanced Solid Tumor Cancers, Medulloblastoma
Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LDE225 given orally on a daily dosing schedule in patients with advanced solid tumors.
- Conditions
- Advanced Solid Tumor Cancers, Medulloblastoma, Basal Cell Carcinoma
- Trial name
- NCT00880308
- Testing
- LDE225
- Where
- 5 sites in United States, Spain and 2 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Basal Cell Carcinoma
Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas
This is a Phase 1 single site study to evaluate the safety and efficacy of a combination therapy that includes the administration of vismodegib and photodynamic therapy (PDT) using aminolevulinic acid (20 percent ALA) for…
- Trial name
- PDT-Vismo (NCT02639117)
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arizona
Skin Cancer
Expression Levels of RISC and Microprocessor Complex Components in Epithelial Skin Cancer
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation.
- Trial name
- NCT01345760
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Ruhr University of Bochum
Basal Cell Carcinoma
Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma
In this study patients with resectable basal cell carcinoma (BCC) who usually undergo surgery without prior anticancer treatment will be treated with antitumor medication.
- Trial name
- NICCI (NCT03035188)
- Testing
- Vismodegib
- Where
- 12 sites in Germany
- Volunteers
- 40 people
- Sponsor
- SRH Wald-Klinikum Gera GmbH
Skin Cancer
An Appearance-Based Intervention to Reduce Teen Skin Cancer Risk
The purpose of this study is to determine whether a skin cancer prevention website is effective at reduce female teenagers' desire to use indoor tanning and ultimately their use of indoor tanning over an 18 month period.
- Trial name
- iSTART (NCT01508013)
- Testing
- Appearance-Focused Website Intervention, Control Website
- Where
- United States
- Volunteers
- 443 people, healthy volunteers welcome
- Sponsor
- East Tennessee State University
Basal Cell Carcinoma
Clinical Diagnosis of Basal Cell Carcinoma Subtype
Skin cancer is the most common cancer in Caucasians. Basal cell carcinoma (BCC) is the most frequent skin cancer with around 44.000 new tumours per year in the Netherlands, and its incidence is still rising.
- Trial name
- NCT01370824
- Testing
- Punch biopsy, Surgical excision
- Where
- 2 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Maastricht University Medical Center
Chronic Leg Ulcers
Interest of a Systematic Biopsy for Hard-to-heal Leg Ulcers
Primary aim of the study : to evaluate the prevalence of ulcerated cutaneous carcinoma or malignant degeneration, in leg ulcers, presumed of vascular origin and without evidence of healing despite 3 months of adequate…
- Trial name
- ULCERE (NCT00709631)
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma
Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype
To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.
- Conditions
- Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Nonmelanoma Skin Cancers
- Trial name
- NMSC (NCT04470726)
- Testing
- AIV001, AIV001 suspension
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- AiViva BioPharma, Inc.
Basal Cell Carcinoma
Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)
A trial to see if BCC excluding the scalp and face can be treated successfully with a combination therapy of Intron-A and Aldara.
- Trial name
- NCT00581425
- Testing
- Imiquimod and Interferon alpha
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- The University of Texas Health Science Center, Houston
Basal Cell Carcinoma
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
This randomized, double-blind, regimen-controlled, phase II, multicenter study will assess the efficacy and safety of two different vismodegib regimens in participants with multiple basal cell carcinoma.
- Trial name
- NCT01815840
- Testing
- Vismodegib
- Where
- 58 sites in United States, Austria and 8 more
- Volunteers
- 229 people
- Sponsor
- Hoffmann-La Roche
Identify Volatile Biomarkers Specific to Malignant Melanoma, Basal Cell Carcinoma and Squamous Cell Carcinoma, Verify That the Volatile Biomarkers Identified Derive From Metabolic Changes in Body Odour and Not Just From Changes in the Surface of Cancerous Lesions
Identification of Olfactory Biomarkers of Skin Cancer From Skin Odor Samples: a Pilot Study
The aim of this research is to determine which volatile organic compounds (odors) are associated with different skin cancers. To this end, odor samples will be taken from various parts of the body, from patients with skin cancers…
- Trial name
- SCENT-SKIN-001 (NCT06493786)
- Testing
- Collection of body odor samples
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Association pour la Recherche Clinique et Immunologique
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS).
- Trial name
- NCT03208296
- Testing
- ASN-002
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ascend Biopharmaceuticals Ltd
Melanoma (Skin), Non-melanomatous Skin Cancer
Isotretinoin in Preventing Skin Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Isotretinoin may be effective in preventing the development or recurrence of skin cancer.
- Trial name
- NCT00025012
- Testing
- isotretinoin
- Where
- United States
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Skin Tumors, Melanoma
Skin Cancer Screening Education Study
The overall aim of this population-based screening study is to assess whether the skin cancer screening training of family physicians and dermatologists leads to improved screening outcomes.
- Conditions
- Skin Tumors, Melanoma, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- SCSES (NCT02352428)
- Testing
- Skin Cancer Screening Training
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Association of Dermatological Prevention, Germany
Basal Cell Carcinoma
Added Value of OCT for Diagnosing Recurrent BCC After Non-invasive Treatment
Superficial basal cell carcinoma (sBCC) can be treated non-invasively, but follow-up is necessary because lesions can reoccur. This study aims to evaluate the additional value of optical coherence tomography (OCT) for the…
- Trial name
- TOBI (NCT05581342)
- Testing
- Punch biopsy (3mm)
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Maastricht University Medical Center